BCR/ABL, mRNA Detection, Reverse Transcription-PCR (RT-PCR), Qualitative, Diagnostic Assay
NY State Approved Indicates the status of NY State approval and if the test is orderable for NY State clients.
Aids in the diagnostic workup for patients with bcr/abl-positive neoplasms, predominantly chronic myeloid leukemia and acute lymphocytic leukemia
When positive, the test identifies which mRNA fusion variant is present to guide selection of an appropriate monitoring assay.
If a quantitative monitoring assay is not available for a rare fusion variant, this assay may be of some value for monitoring, as it is quite sensitive and can provide a positive or negative result.
Testing Algorithm Delineates situation(s) when tests are added to the initial order. This includes reflex and additional tests.
The following algorithms are available in Special Instructions:
-Myeloproliferative Neoplasm: A Diagnostic Approach to Bone Marrow Evaluation
-Myeloproliferative Neoplasm: A Diagnostic Approach to Peripheral Blood Evaluation
Special Instructions and Forms Describes specimen collection and preparation information, test algorithms, and other information pertinent to test. Also includes pertinent information and consent forms to be used when requesting a particular test
Reverse Transcription-Polymerase Chain Reaction (RT-PCR) with Fluorescent-Bead Array Analysis
(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
Reporting Name A shorter/abbreviated version of the Published Name for a test; an abbreviated test name
BCR/ABL, RNA-Qual, Diagnostic
Philadelphia Chromosome Ph1 Bone Marrow/Blood